- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 211/28 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
Patent holdings for IPC class C07D 211/28
Total number of patents in this class: 97
10-year publication summary
|
6
|
11
|
5
|
8
|
11
|
5
|
9
|
2
|
4
|
1
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Merck Sharp & Dohme Corp. | 2183 |
6 |
| Life Technologies Corporation | 3456 |
5 |
| The Regents of the University of California | 20720 |
3 |
| Eastern Virginia Medical School | 64 |
3 |
| The Regents of the University of California, Santa Cruz | 17 |
3 |
| Thomas Jefferson University | 554 |
3 |
| Grey Wolf Therapeutics Limited | 17 |
3 |
| Boehringer Ingelheim International GmbH | 4493 |
2 |
| Takeda Pharmaceutical Company Limited | 2715 |
2 |
| Constellation Pharmaceuticals, Inc. | 218 |
2 |
| D. E. Shaw Research, LLC | 12 |
2 |
| Leidos Biomedical Research, Inc. | 41 |
2 |
| The Research Foundation for The State University of New York | 1738 |
2 |
| Universität Konstanz | 75 |
2 |
| The United States of America Department of Health | 2 |
2 |
| Nanjing Immunophage Biomedical Co., Ltd. | 9 |
2 |
| Bristol-myers Squibb Company | 4729 |
1 |
| F. Hoffmann-La Roche AG | 7836 |
1 |
| Hoffmann-La Roche Inc. | 3783 |
1 |
| Syngenta Crop Protection AG | 6699 |
1 |
| Other owners | 49 |